← Leaderboards
Rochelle P Walensky
Massachusetts General Hospital
$10,475,833
Attributed
$10,475,833
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $938.4K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,475,833 · 4
By mechanism
R01$6,071,160 · 2
R37$3,754,918 · 1
K23$649,755 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Krishna P Reddy$8,351,137
- Andrea Lynne Ciaranello$11,011,193
- Emily Parker Hyle$5,946,835
- Anne Neilan$4,903,623
- Richard T D'aquila$62,924,506
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventInfectionCostDesignPoliciesBaseMedicineResearch PersonnelUnited States National Institutes Of HealthEvaluationCost EffectivenessAreaClinical Trials DesignBackAids Clinical Trial GroupEnvironmentAcquired Immunodeficiency SyndromeEnrollmentHiv DiagnosisCaringBudgetsComputer SimulationGoldClinical Trials
Grant awards (20)
Novel Methods to Inform HIV/TB Clinical Trial Development$745,684
R37 · FY2019 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$732,206
R37 · FY2018 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$745,409
R37 · FY2017 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$731,458
R37 · FY2016 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$800,161
R37 · FY2015 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$580,139
R01 · FY2014 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$358,268
R01 · FY2014 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$545,328
R01 · FY2013 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$580,325
R01 · FY2012 · AI · contact PI
Novel Methods to Inform HIV/TB Clinical Trial Development$664,504
R01 · FY2011 · AI · contact PI
Optimizing strategies for universal HIV testing$535,690
R01 · FY2010 · MH · contact PI
Optimizing strategies for universal HIV testing$700,368
R01 · FY2009 · MH · contact PI
Optimizing strategies for universal HIV testing$640,975
R01 · FY2008 · MH · contact PI
Optimizing strategies for universal HIV testing$811,825
R01 · FY2007 · MH · contact PI
Optimizing strategies for universal HIV testing$653,738
R01 · FY2006 · MH · contact PI
Treatment Models for Primary and Chronic HIV Infection$129,951
K23 · FY2005 · AI
Treatment Models for Primary and Chronic HIV Infection$129,951
K23 · FY2004 · AI
Treatment Models for Primary and Chronic HIV Infection$129,951
K23 · FY2003 · AI
Treatment Models for Primary and Chronic HIV Infection$129,951
K23 · FY2002 · AI
Treatment Models for Primary and Chronic HIV Infection$129,951
K23 · FY2001 · AI